It has been reported that sleeve lobectomy (SL) concomitant with or without pulmonary artery reconstruction (PAR) might be an alternative procedure for pneumonectomy (PN) in non-small cell lung cancer (NSCLC). The aim of this study was to assess whether SL or PN offers a low morbidity and mortality and better long-term survival. We performed a meta-analysis of studies published in English between 1996 and 2006 to comprehensively compare the postoperative mortality, morbidity, locoregional recurrences, and time-to-event outcomes of SL and PN in NSCLC, and reviewed the recent literatures on PAR in the corresponding period as well. Twelve studies met the defined criteria including a total of 2984 subjects, and five studies for PAR. The odds ratio for postoperative mortality (SL vs PN) was 0.65 (95% confidence interval (CI): 0.42-1.01), 1.01 (95% CI: 0.70-1.44) for postoperative complications, and 0.91 (95% CI: 0.45-1.82) for locoregional recurrences. The weighted mean operative mortality for PAR was 3.3%, and 32.4% for complications. The estimated combined hazard ratio for overall survival in 10 studies was 0.70 (95% CI: 0.62-0.79) in favor of SL group. The median overall survival was 60 months for the SL group, 26 months for the PN group, and 30 months for PAR group. Survival difference in patients with pN0 or pN1 at 1 year demonstrated a pooled risk difference (SL vs PN) of 0.03 (95% CI: À0.08-0.13), 0.13 (95% CI: 0.00-0.25) in patients with pN2 at 1 year, 0.21 (95% CI: 0.07-0.36) in patients with pN0 or pN1 at 5 years, and 0.06 (95% CI: À0.10-0.21) in patients with pN2 at 5 years. Our results suggests that SL with or without PAR can be accomplished safely in selected patients without increasing the morbidity and mortality as compared to PN, that SL even with PAR offers better long-term survival than does PN, and that a more radical operation such as PN is not a more appropriate procedure, even in higher stage tumors. #
Introduction
Lung cancer, accounting for 32% and 24% of cancer deaths in men and women, respectively, represents the leading cause of cancer death worldwide. Approximately 75-80% of lung cancers are of the non-small cell lung cancer (NSCLC) histology. The overall 5-year survival rate of NSCLC is only 8-14% when diagnosed and this rate increases to 40% after complete surgical resection [1, 2] . Great efforts have been made in the surgical procedure for the treatment of NSCLC. In 1933, Graham and Singer [3] performed the first successful one-stage pneumonectomy (PN) for lung cancer. After this successful operation, penumonectomy became the standard treatment for central or locally advanced NSCLC for the next two decades. Price-Thomas [4] reported in 1947 the first bronchial sleeve resection for carcinoid tumor and Allison [5] performed the first sleeve lobectomy (SL) for bronchogenic carcinoma in 1954. Since then, SL has been regarded as the standard management of NSCLC for patients who were believed to be incapable of tolerating a PN because of an inadequate pulmonary reserve, resulting from lung-parenchyma-sparing advantage.
Currently, SL is prone to be performed for such patients who could tolerate PN. Several studies have shown that longterm survival after SL is at least similar to or even better than that after PN with lower postoperative risks, better preservation of lung function, and better quality of life [6] [7] [8] . However, SL has been reported with a high bronchial postoperative complication [9] [10] [11] and a high operative mortality relative to PN [10, 12, 13] , owing to the complex surgical procedure for SL. In contrast, other study pointed out that PN is associated with significant morbidity and mortality [14] , including postpeumonectomy lung edema, acute respiratory distress syndrome (ARDS), bronchopleural fistula, and postpeumonectomy syndrome. Nonetheless, there are several reports revealing that PN does not adversely influence long-term survival [15, 16] .
In addition, when lung tumors involve not only the airway but also the central vascular structures, in particular the pulmonary artery, SL concomitant with pulmonary artery reconstruction (PAR) (double sleeve) remains as the only alternative to PN. However, this procedure has been slower to gain acceptance than reconstruction of bronchus alone.
This study aims to assess whether SL concomitant with or without PAR or PN offers a low morbidity and mortality and better long-term survival by mata-analysis which evaluate the published literature in a qualitative and quantitative way by comparing and integrating the results of different studies.
Materials and methods

Strategy of literature search
A PubMed search of studies published in English from 1996 to 2006 and reporting on SL for NSCLC and comparing this to PN was performed using the key words 'sleeve resection or lobectomy and/or pneumonectomy' and 'lung neoplasm'. Studies on PAR were also searched by the key words 'pulmonary artery reconstruction or pulmonary artery sleeve resection or bronchovascular sleeve resection'. All abstracts were reviewed and the 'related articles' function was employed to broaden the search on appropriate abstracts.
Data extraction
Two reviewers independently extracted the following data from each study: first author, year of publication, study population characteristics, study size, study design, definition of mortality and recurrences, inclusion and exclusion criteria, time of follow-up, and survival data.
Survival data were sourced from the literature. The summary statistics included the log hazard ratios (log HRs) or hazard ratio (HRs) and associated variances. Estimation of the log HR and variance were from the published survival curves according to the methods suggested by Parmar et al. [17] . Briefly, survival probabilities for SL and PN were read from the survival curves at pre-specified non-overlapping time points. The number of patients alive and at risk was calculated for each time interval, as well as the effective number of patients censored, to generate the log HR and its variance during each time interval. As the log HRs are independent, an estimate of the overall log HR for each study can be given by a weighted sum of the individual estimates of the log HR during each time interval, using the inversevariance weighting method [18] .
Inclusion and exclusion criteria
Studies included in our analysis had to: 
Definition of outcomes of interest
SL and PN were compared with postoperative mortality, postoperative complications, locoregional recurrences, as well as survival outcomes. Survival outcome measures were analyzed by the difference of survival of the two techniques at 1 and 5 years, the difference of survival in patients with pN0 or pN1 and pN2 at 1 and 5 years, and overall survival.
Statistical analysis
Meta-analysis was carried out using odds ratio (OR), risk difference (RD), and HR as the summary statistics. The OR represents the odds of an adverse event occurring in the treatment (SL) group in comparison to the reference (PN) group. The RD means the difference of survival of patients subjected to two techniques at 1 and 5 years. An OR of less than 1, while a RD more than 0 favors SL group, and the point of estimate of the OR and RD is considered statistically significant at the p < 0.05 level if the 95% confidence interval does not include the value 1 or 0, respectively. Yate's correction was used for those studies without events of interest in one of the two groups, which results in problems with the calculation of ratios and their standard error of the treatment effect. To solve this problem, we have added the conventional 0.5 to each cell in the contingency table of these trials [19] .
In our study both fixed and random effect models were employed. The fixed effect model is based on the assumption that the treatment effect in each study is same, whereas the random effect model is based on the assumption that there is variation between studies. Thus, the ratios calculated in the random effect model are more conservative than those calculated in the fixed effect model [20] . In a meta-analysis of surgical research, the random effect model is preferable due to a number of sources of heterogeneity (HG) including varying risk profiles, selection criteria for each surgical technique, study design, study start date, and duration of follow-up [21] .
The most appropriate summary statistics for survival-type data are the log HR and its variance, which allows for both censoring and time to an event [17] . Survival data were pooled by the DerSimonian and Laird method to produce a random effect meta-analysis. Heterogeneity between studies was investigated by the standard chi-squared Q-test. Pooled survival curve [22] across all studies for SL versus PN was generated, utilizing the methodology to estimate the log HR; however, the survival probabilities were extracted at a common series of time points, then pooled.
To determine clinical benefits of two techniques, three parameters were calculated: absolute reduction (ARR), which in this case is the difference in the incidence of events between SL and PN groups; number needed to treat (NNT), which is the number of patients who must be treated (in this case to be operated by SL) in order to prevent one event (NNT = 1/ARR); and median survival times and associated variances which were estimated from the pooled survival curve.
Analysis was performed by SPSS version 13.0 for Windows (SPSS Inc., Chicago, IL, USA), Microsoft Excel 2002 (Microsoft Corporation, USA), and Review Manager Version 4.2 (The Cochrane Collaboration, Oxford).
To quantitatively assess heterogeneity between studies, three strategies were employed as reported previously [21] . First, data were re-analyzed using both fixed-and random effect models. Secondly, publication bias was assessed by funnel plot. Thirdly, subgroup analysis was used for sensitive analysis. In subgroup analysis, the following variables were used:
1. All studies 2. Matched study 3. Study size (more than 50 patients in each group) 4. Year of publication (inclusive of or greater than 2000)
Results
Selected studies
Thirteen articles [6, 8, [10] [11] [12] [23] [24] [25] [26] [27] [28] [29] [30] published between 1996 and 2006 met our inclusion criteria comparing SL versus PN for NSCLC. One of these was excluded, resulting from comparing SL versus sleeve pneumonectomy [27] . Finally, 12 studies, including 3 matched studies [6, 10, 24] and 1 prospective study [8] , were suitable for meta-analysis, with a combined total of 2984 subjects, of which 876 (29%) underwent SL and 2108 (71%) underwent PN. A small portion of patients (8.9%) in six studies [6, 8, 10, 11, 12, 24] in SL group underwent SL combined with PAR. Five studies [30] [31] [32] [33] [34] including 202 subjects were retrieved reporting on PAR alone or associated with lobectomy or bronchial sleeve resection, among which there were 164 patients (81.2%) subjected to PAR concomitant with SL.
In Tables 1 and 2 are the characteristics of these studies. The distribution of stage between the SL group and the PN group was significantly different (stages I, II, and III: 37%, 37%, and 26% for SL; 20%, 33%, and 47% for PN; p < 0.001; 10 reports). Sex ratios for the two surgical groups showed statistically significant difference as well (male/female: 65%/35% for SL; 71%/29% for PN; p < 0.001; 11 reports). However, there was no difference in mean ages for the two groups (61.6 years for SL; 60.8 years for PN), although age distributions were not available.
Postoperative mortality
The postoperative mortality was reported in 12 studies [6, 8, [10] [11] [12] [23] [24] [25] [26] [28] [29] [30] and meta-analysis of the resultant data showed the pooled postoperative mortality in SL was 3.5% (31/876) as compared with 5.7% (121/2108) in PN, but did not reach statistical significance (OR: 0.65; 95% CI: 0.42-1.01), as shown in Fig. 1 F, fixed effect model; R, random effect model; OR, odds ratios (95% CI); RD, risk difference (95% CI); HG, heterogeneity (x 2 ); P: p-value of heterogeneity; EV, number of adverse events (a patient may have had more than one event); SN, number of survival; SL, sleeve lobectomy; PN, pneumonectomy.
The weighted mean operative mortality reported in four studies [30] [31] [32] 34] for PAR was 3.3%, which was not statistically significant as compared with SL group, while it was significantly lower than that of PN ( p < 0.05).
Postoperative complications
Eight studies [6, [10] [11] [12] 23, 24, 26, 29] reported the incidence of postoperative complications, and meta-analysis of these studies gave a pooled incidence of 31.3% (154/492) with SL and 31.6% (245/776) with PN (OR: 1.01; 95% CI: 0.70-1.44), which was not statistically significant (Fig. 1) . The calculated ARR for SL versus PN was 0.3%, indicating the NNT would be 333. Subgroup analysis of studies with at least 50 patients in each group [6, 11, 12, 23, 29] produced an incidence of 30.8% (116/376) in SL as compared with 33.6% (192/ 571) in PN (OR: 0.93; 95% CI: 0.59-1.48), not revealing any significant difference between the two groups. Similar The weighted mean postoperative complications reported in three studies [31, 32, 34] for PAR was 32.4%, which was neither statistically significant as compared with SL group, nor was it significantly lower than that of PN.
Locoregional recurrences
This was reported in six studies [6, 10, 12, 24, 28, 29] and meta-analysis of the resultant data showed the pooled locoregional recurrence in SL was 16 [6, 12, 28, 29] with more than 50 patients in each group, the incidence of locoregional recurrences was 14.5% (54/ 372) with SL compared with 28.7% (392/1367) with PN, suggesting that this is statistically significant (OR: 0.58; 95% CI: 0.42-0.80).
Overall survival
Survival data from 10 studies [6, [10] [11] [12] [24] [25] [26] [28] [29] [30] were extracted, including 2708 patients, 761 in the SL group and 1947 in the PN group. A summary of individual studies and overall pooled survival is shown in Fig. 2 . The estimated combined HR for overall survival in 10 studies was 0.70 (95% CI: 0.62-0.79) in favor of SL group, which was statistically significant. Subgroup analysis of studies with at least 50 patients in each group [6, 11, 12, 25, [28] [29] [30] (HR: 0.69; 95% CI: 0.61-0.78), and only recent studies [6, [10] [11] [12] 26, [28] [29] [30] (HR: 0.71; 95% CI: 0.63-0.80) reached statistically significant difference. This result was reproduced in the case of matched studies [6, 10, 24] , where the HR was 0.66, with 95% CI of 0.46-0.96.
The pooled survival curves (10 reports for SL and PN, 4 reports for PAR [30] [31] [32] 34] ) based on Kaplan-Meier calculations are shown in Fig. 3 . The median overall survival was 60 months for the SL group, 26 months for the PN group, and 30 months for the PAR group. The overall 5-year survival was 50.3% for the SL group, 30.6% for the PN group, and 38.7% for the PAR group.
Difference of survival at 1 year
Differences of survival at 1 year were extracted from 10 studies [6, [10] [11] [12] [24] [25] [26] [28] [29] [30] and meta-analysis of these studies showed a combined RD was 0.10 (95% CI: 0.07-0.14) in favor of the SL group (Fig. 4) . Similar results were achieved when only recent studies [6, [10] [11] [12] 26, [28] [29] [30] were considered (RD: 0.10; 95% CI: 0.05-0.14). This finding was reproduced in the case of the studies [6, 11, 12, 25, [28] [29] [30] with more than 50 patients in each group, where the RD was 0.12 (95% CI: 0.08-0.15). Concerning the matched studies [6, 10, 24] , the pooled RD was 0.06 (95% CI: À0.04-0.16), suggesting that this is not statistically significant.
Difference of survival at 5 years
Differences of survival at 5 years were extracted from nine studies [6, [10] [11] [12] 25, 26, [28] [29] [30] and meta-analysis of these studies showed a combined RD was 0.12 (95% CI: 0.07-0.18) in favor of the SL group (Fig. 4) . Similar results were achieved when only recent studies [6, [10] [11] [12] 26, [28] [29] [30] were considered (RD: 0.15; 95% CI: 0.10-0.19). This finding was reproduced in the case of the studies [6, 11, 12, 25, [28] [29] [30] with more than 50 patients in each group, where the RD was 0.12 (95% CI: 0.05-0.19). Considering the matched studies [6, 10] , the pooled RD was 0.12 (95% CI: À0.01-0.24), which was not statistically significant.
Differences of survival in patients with pN0 or pN1 and pN2 at 1 and 5 years
Two studies [6, 11] reported the survival in patients with pN0, pN1, and pN2 at 1 and 5 years, as shown in Fig. 4 . Metaanalysis of difference of survival in patients with pN0 or pN1 at 1 year demonstrated a pooled RD (SL vs PN) was 0.03 (95% CI: À0.08-0.13), which was not statistically significant. When difference of survival in patients with pN2 at 1 year was considered, the combined RD was 0.13 (95% CI: 0.00-0.25), and just reached statistical significance. Meta-analysis of difference of survival in patients with pN0 or pN1 at 5 years showed that pooled RD was 0.21 (95% CI: 0.07-0.36), which was statistically significant. Considering difference of survival in patients with pN2 at 5 years, the combined RD was 0.06 (95% CI: À0.10-0.21), indicating there was no difference between two groups. 
Sensitivity analysis
In our study both fixed-and random effect models were employed for sensitivity analysis. The results for events in the SL group and PN group are shown in Table 3 . As for postoperative mortality, the heterogeneity test showed a lowest heterogeneity when only recent studies were considered (HG = 7.42, p = 0.49). Similar results were achieved when the studies of more than 50 patients in each group were concerned (HG = 5.47, p = 0.60). This finding was reproduced in the case of matched studies (HG = 1.64, p = 0.44). With regard to postoperative complications, the heterogeneity test showed HG was 5.05 ( p = 0.08) for matched studies, 8.27 ( p = 0.08) for the studies of more than 50 patients in each group, and 9.84 ( p = 0.08) for recent studies. In the case of locoregional recurrences, the sensitivity analysis resulted in significant heterogeneity when the matched studies or the recent studies were considered, with HG of 7.24 ( p = 0.02), 13 .66 ( p = 0.008), respectively, while still remaining relatively low heterogeneity (HG = 1.59, p = 0.66) in the studies of more than 50 patients in each group.
When it comes to difference of survival at 1 year, the sensitivity analysis showed HG was 2.86 ( p = 0.24) for matched studies, 5.32 ( p = 0.50) for the studies of more than 50 patients in each group, and 8.51 ( p = 0.29) for recent studies. This finding was repeated in the sensitivity analysis of difference of survival at 5 years, with HG of 0.11 ( p = 0.74) for matched studies, HG of 12.64 ( p = 0.05) for the studies of more than 50 patients in each group, and HG of 7.70 ( p = 0.36) for recent studies. Fig. 4 . Meta-analysis of selected studies comparing differences of survival in patients with pN0 or pN1 and pN2 at 1 and 5 years between the sleeve lobectomy group and the pneumonectomy group.
Publication bias was assessed using a funnel plot (Fig. 5) which showed the 12 studies used in our meta-analysis. The scatter plot resembles a symmetric inverted funnel (the 95% confidence interval), in which the treatment effects estimated from individual studies on the horizontal axis (OR), against a measure of study size on the vertical funnel (SE [log OR]). The plot is on the basis that precision in the estimation of the underlying treatment effect will increase with the increment of the sample size of the component studies [21] .
Discussion
Our meta-analysis study included a total of 2984 subjects, of which 876 (29%) underwent SL and 2108 (71%) underwent PN. A sample group of this size would otherwise be impossible to accumulate in a reasonable length of time in a single institute. The stage distribution between the SL group and the PN group was significantly different (stages I, II, and III: 37%, 37%, and 26% for SL; 20%, 33%, and 47% for PN; 10 reports), indicating that SL is prone to be performed in earlystage NSCLC and may have a better prognosis.
The postoperative mortality, postoperative complications, and locoregional recurrences between the two groups did not differ significantly. It is worth noting that the postoperative mortality after SL (3.5%) approached statistical significance as compared with 5.7% after PN. Furthermore, in the fixed effect model, the postoperative mortality between the two groups was significantly different, which is in line with a meta-analysis [35] of comparisons between SL and PN in stage I and II NSCLC. In that study, the weighted mean postoperative mortality after SL was 4.1%, and 6.0% after PN.
In the time-to-event analysis, the HR is one of the most appropriate effect indexes to evaluate time-related effect of surgical procedures [17] . The death risk decreased by 30% in SL group compared with PN group. Moreover, as for survival probability difference, there was an increase trend, that was 12% at 1 year and 19% at 5 years. Median overall survival was increased in the SL group as well (60 months vs 26 months). However, the previous meta-analysis study [35] showed that 5-year survival rates were similar for the two techniques (SL: 51% vs PN: 49%) when corrections for stage distribution were calculated, that use of 5-year survival rate as an outcome in the decision model slightly favored SL over PN for managing stage I and II NSCLC, and that the mean median survivals were 70.5 months for SL and 55.2 months for PN, which was statistically significant.
The relationship between survival and lymph node status is unclear after patients were subjected to SL or PN. Our study demonstrated that survival difference in patients with pN2 at 1 year just reached statistical significance, that in patients with pN0 or pN1 at 5 years showed statistical difference, and that in patients with pN2 at 5 years indicated there was no difference between two groups. Our results were in agreement with another study [28] which reported that there was significant difference in 5-year survival between SL and PN for patients with pN0 or pN1, whereas 5-year survival for patients with pN2 or stage III disease was not significant. Together with the results indicate that a more radical operation such as PN is not a more appropriate procedure, even in higher stage tumors.
When only the matched studies were concerned, there were no significant differences for postoperative mortality, postoperative complications, locoregional recurrences, survival difference at 1 year, or survival difference at 5 years between the two techniques. Therefore, further studies with strict criteria and good study design are needed to investigate the clinical benefits of two techniques.
There have been rare reports on PAR in the literature so far, which may in part due to high risk, complicated surgical procedures, and decreased long-term survival [13] . Our meta-analysis on recent results showed that the surgical outcomes of PAR were not only comparable to SL with 3.3% for the operative mortality, 32.4% for the postoperative complications, and 38.7% for the 5-year survival, but better than those of PN. These indicate that PAR combined with SL is as safe as SL for the treatment of NSCLC.
The limitations of our meta-analysis were as follows. First, definitions for postoperative mortality and locoregional recurrences were different, as illustrated in Table 1 . Secondly, stage distribution between the SL group and the PN group was quite different, which might lead to unreliable results and favor the SL group. Thirdly, no randomized data were available for comparing SL and PN and the treatment protocol for NSCLC was somewhat different among institutions, all of which made the analysis and comparison difficult. Fourthly, it is of great importance to bear in mind publication bias, especially in meta-analytic research based on published retrospective studies. Fifthly, the absence of generalized and commonly shared guidelines for the set-up and data reporting also disturbed our meta-analysis. Sixthly, the population in PAR group is quit small as compared with the SL or PN group.
In the present study, 16 of the 17 studies were retrospective because a randomized prospective trial is not possible to perform. The reason for this difficulty is: (1) the final decision to perform SL or PN has to be taken during the operative procedure; (2) the small number of cases available for study; and (3) the definition of eligibility. Despite the obvious bias related to retrospective nature, meta-analysis of these non-randomized studies provides the most reliable information, which is a suggested approach to search for the 'best evidence' in the absence of well-controlled randomized studies [36] .
In summary, our study demonstrates that SL with or without PAR is effective and can be accomplished safely in selected patients without increasing the morbidity and mortality as compared to PN, that SL even with PAR offers better long-term survival than does PN, and that a more radical operation such as PN is not a more appropriate procedure, even in higher stage tumors.
